In cardiovascular outcome trials, sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have lowered the risk of major adverse cardiovascular events.6–12 Secondary kidney outcomes in these cardiovascular outcome trials have suggested kidney benefits.6–16 In the first designated T2D kidney outcome trials, the sodium-glucose cotransporter-2 inhibitors canagliflozin and dapagliflozin were shown to substantially lower the risk of hard kidney outcomes compared with placebo (patients with and without T2D were included in the latter trial).17,18. Here, SLC5A2 is linked to type 2 diabetes mellitus.